Results 141 to 150 of about 64,876 (258)

Expression of Nectin‐4 and Trop‐2 in upper tract urothelial carcinoma: implications for biomarker‐driven antibody‐drug conjugate therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Recent advancements in antibody‐drug conjugates, including FDA‐approved therapies targeting Nectin‐4 and Trop‐2, have transformed the cancer treatment landscape, including upper tract urothelial carcinoma (UTUC). However, varied treatment effects and drug‐associated adverse effects raise the question of whether patients should be selected ...
Ping Shi, Qingqing Wu, Yong Zhang, Tiane Chen, Joshua I. Warrick, David J. DeGraff, Jay D. Raman, Guoli Chen   +7 more
wiley   +1 more source

Urothelial carcinoma occurring in a defunctionalized bladder after urinary diversion due to the bladder exstrophy‐epispadias complex

IJU Case Reports
Introduction The bladder exstrophy‐epispadias complex is a rare congenital disease. Urothelial carcinomas rarely occur in patients with this disease, and there have been few reports on its treatment.
Toshiharu Morikawa, Shoichiro Iwatsuki, Aya Naiki‐Ito, Masakazu Gonda, Kazumi Taguchi, Taku Naiki, Shuzo Hamamoto, Atsushi Okada, Takahiro Yasui   +8 more
doaj   +1 more source

Non‐Functional Paraganglioma of the Urinary Bladder: A Rare Cause of Bladder Tumor

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Paragangliomas of the urinary bladder (PUBs) are rare neuroendocrine tumors, representing less than 0.06% of all bladder neoplasms. While most are functional and associated with catecholamine excess, approximately 15% are non‐functional, often presenting asymptomatically and discovered incidentally.
Matt Wainstein, Vivek Aslot, Faith Dennie, Mark Wainstein, Thenappan Chandrasekar   +4 more
wiley   +1 more source

Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Anti‐melanoma differentiation‐associated gene 5 antibody‐positive interstitial lung disease is a rare but fatal adverse event following immune checkpoint inhibitor treatment for cancers. However, such cases have not been previously reported in patients with urothelial carcinoma.
Akira Saito, Hiroki Ishihara, Hanae Kondo, Toshio Takagi, Yasunobu Hashimoto   +4 more
wiley   +1 more source

Early Recognition of Immune‐Related Hepatitis During Avelumab Maintenance Therapy for Urothelial Carcinoma

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Avelumab is recommended as maintenance therapy for advanced urothelial carcinoma after platinum chemotherapy; however, immune‐related adverse events can be severe and refractory. Case Presentation A 79‐year‐old male developed immune‐related hepatitis during avelumab maintenance therapy following gemcitabine plus carboplatin for ...
Yuka Iwama, Tomoyasu Sano, Yuta Sano, Tomokazu Kimura, Yushi Naito, Satoshi Inoue, Kazuna Matsuo, Shohei Ishida, Yoshihisa Matsukawa, Shusuke Akamatsu   +9 more
wiley   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

GATA3 is a sensitive marker for primary genital extramammary paget disease: An immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15 [PDF]

, 2017
Cao, Dengfeng, et al,
core   +2 more sources

Risk of metachronous upper tract urothelial carcinoma following non‐muscle‐invasive bladder cancer

BJU International, Volume 137, Issue 3, Page 502-508, March 2026.
Objective To determine the risk and timing of metachronous upper tract urothelial carcinoma (UTUC) after non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods In this multi‐institutional retrospective cohort study involving academic and community hospitals, clinicopathological data were collected from patients with NMIBC treated between 2005
Keiran J.C. Pace, Jethro C.C. Kwong, Harkanwal Randhawa, Maximiliano Ringa, Zizo Al‐Daqqaq, Yashan Chelliahpillai, Soomin Lee, Kellie Kim, Samuel Haile, Amna Ali, Marian Wettstein, Amy Chan, Nathan Perlis, Jason Lee, Robert Hamilton, Neil Fleshner, Antonio Finelli, Munir Jamal, Frank Papanikolaou, Thomas Short, Andrew Feifer, Girish Kulkarni, Alexandre R. Zlotta   +22 more
wiley   +1 more source

Personalized Models of Biological Barriers and Their Diseases: Recent Progress with Organs‐On‐Chips

Advanced Biology, Volume 10, Issue 2, February 2026.
Buck and Bugter et al. explore the architectural diversity and physiological functions of human barrier systems and reveal how organ‐on‐chip platforms, particularly those integrating patient‐derived cells, are advancing barrier disease modeling. They highlight how emerging biological and technological advances can be used to bridge the gap between ...
Franziska Buck, Jeroen Bugter, Gizem Yorukoglu, Mina Kazemzadeh Dastjerd, Thomas E. Winkler   +4 more
wiley   +1 more source